Contact us : info@bioworlde.com
Home > Product > Cytokine & Recombinant Proteins
Recombinant Viral Macrophage Inflammatory Protein-2 (rvMIP-2) PR6002
RecombinantRecombinant Viral Macrophage Inflammatory Protein-2 (rvMIP-2)
Catalog No.PR6002
SourceEscherichia coli.
Molecular Weight7.9 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids.
Purity>97% by SDS-PAGE and HPLC analyses.
Biological ActivityFully biologically active when compared to standard. Determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha, corresponding to a Specific Activity of >100 IU/mg.
Physical AppearanceSterile Filtered White lyophilized (freeze-dried) powder.
FormulationLyophilized from a 0.2m filtered concentrated solution in 20mM PB, pH 7.4, 150mM NaCl.
EndotoxinLess than 1EU/g of rvMIP-2 as determined by LAL method.
Browse similar products>>
Size Price
10µg $158
50µg $298
1.0mg $enquire
Add to cart My orders
Recombinant :
Recombinant Viral Macrophage Inflammatory Protein-2 (rvMIP-2)
Source :
Escherichia coli.
Molecular Weight :
7.9 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids.
Purity :
>97% by SDS-PAGE and HPLC analyses.
Biological Activity :
Fully biologically active when compared to standard. Determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/ml of viral MIP-2 will inhibit 25ng/ml of human MIP-1 alpha, corresponding to a Specific Activity of >100 IU/mg.
Physical Appearance :
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation :
Lyophilized from a 0.2m filtered concentrated solution in 20mM PB, pH 7.4, 150mM NaCl.
AA Sequence :
LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA
Endotoxin :
Less than 1EU/g of rvMIP-2 as determined by LAL method.
Reconstitution :
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions.
Storage :
This lyophilized preparation is stable for several weeks at 2-8C, but should be kept at -20C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -70C. Avoid repeated freeze/thaw cycles.
Usage :
This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. Made in China
Description :
Viral MIP-2 cDNA encodes a 94 amino acid residue precursor protein with a 23 aa residue signal peptide that is cleaved to yield a 71 aa residue mature protein. Among human chemokines, vMIP-2 is most closely related to MIP-1α, sharing approximately 41% amino acid sequence identity. At the amino acid sequence level, vMIP-1 and vMIP-2 also share 48% identity. vMIP-1 and vMIP-2 are more closely related to one another phylogenetically than to other human chemokines, suggesting that they may have arisen by gene duplication within the virus rather than by two independent gene aquisitions. vMIP-2 binds to the CCR3 chemokine receptor through which eotaxin and other β chemokines activate eosinophils. vMIP-2 has been shown to activate and chemoattract human eosinphils.
Blocking peptide available as PR6002P
COPYRIGHT © 2015-2018 Bioworld Technology, Inc. All rights reserved POLYCLONAL AND MONOCLONAL ANTIBODY CENTER